By merging components of four different hormones into a single drug, researchers aim to combat obesity while also tackling related conditions such as type 2 diabetes, cancer, and cardiovascular ...

Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...